Nearly two-thirds of Canadians oppose longer patents for brand-name drugs under a proposed trade deal with the European Union, according to a poll commissioned by the Council of Canadians.
Following the public outcry over the EU’s demands for stringent intellectual property rules that would dramatically raise medicines prices in India, you would expect the EU to think twice about making similar demands in future trade agreements. Yet, this is precisely what is going on now in the negotiations for a free trade agreement between the EU and Thailand.
There are apprehensions that TTIP would prevent Indian pharma companies to come to market with the same products - they would need to pass through several rounds of additional tests. As a result, prices will move up significantly.
Leaked details of free trade negotiations between New Zealand and the United States show the two countries are in stark opposition on a number of key areas.
Since announcing the Comprehensive Economic and Trade Agreement (CETA) two weeks ago Harper’s Conservatives have repeatedly labelled those questioning the deal as “anti-trade”. But this Canada-European Union accord is one part trade and four parts ‘corporate bill of rights’.
The federal government won’t release internal documents that may predict potential higher drug costs for Canadians under new patent rules agreed to in the free-trade deal with Europe, Trade Minister Ed Fast says.
The far reaching provisions of the Comprehensive Economic and Trade Agreement between Canada and the European Union will have considerable impact on Canada’s IP regime.
The struggle for access to medicine presents a legal and ethical minefield for rich and poor countries alike—one that is being fought out as humanitarians challenge corporations over intellectual property rights.
India is facing an onslaught of political pressure from the U.S. government and pharmaceutical industry in retaliation for the country’s entirely legal actions to limit abusive patenting practices and increase access to affordable generic medicines
Thai trade representative Olarn Chaiprawat has given civil society groups a confirmation that "TRIPS-plus" and drug issues will not be included in the Thai-EU FTA negotiations.
Once again, our government is negotiating a trade deal in secret — and once again, the chorus of “free market” fundamentalists is assuring us that what’s good for lining corporate pockets must be good for us all.
Malaysia should exclude medical and tobacco businesses in the ongoing free trade talks under the Trans-Pacific Partnership Agreement (TPPA).
Canada is pushing back against a campaign by activists trying to block what they say are onerous intellectual property rules that would raise the price of pharmaceuticals in poor countries.
As host to both the AIDS conference and TPP trade talks this month, Malaysia reportedly vows to reject a TPP trade agreement that harms access to medicines; other countries should follow suit, and Malaysia should be held to its pledge
Bilateral investment treaties (BITs) may be a threat to access to medicines as shown by a recent legal suit by a drug multinational against Canada for invalidating a patent, writes Carlos Correa
Are the PBS and Pharmac under threat from the TPP? Certainly, the respective governments of both Australia and New Zealand think not. So why then the paranoia? Quite simply, we need the US more than they need us. In order to secure the TPP (and with it, for example, access to the lucrative US dairy market), both Australia and New Zealand will likely need to yield in several key areas.
There is a strong sense in the halls of the current TPP negotiation that the end is not in sight. And one of the primary reasons s a lack of consensus on intellectual property and pharmaceuticals issues, reports Infojustice from Lima.
Although access to medicines activists have been wise to focus our attention intently on convincing low- and middle-income countries to adopt and use all possible TRIPS-compliant flexibilities and to oppose the TRIPS-plus IP chapters in free trade agreements, we have neglected to interrogate another chapter in free trade agreements and bilateral investment treaties that perhaps pose an even greater threat to our collective access to medicines – investment chapters.
The much-hyped bilateral trade and investment agreement (BTIA) between India and the European Union (EU) would not impact the Indian generic drugs industry or lead to a change in the country’s patent law, João Cravinho, EU ambassador to India, said on Friday.
A large number of people living with HIV, cancer patients and health activists took to the streets of Delhi today asking government of India not to sign a Free Trade Agreement (FTA) with the European Union (EU) as it would be detrimental to the interests of tens of thousands of people like them in the country.